WHO ICTRP trial
Alternating treatment of venetoclax plus azacytidine (VA) with azacytidine plus…
ChiCTR2400094653 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2400094653 |
|---|---|
| Public title | Alternating treatment of venetoclax plus azacytidine (VA) with azacytidine plus homoharringtonine, low-dose cytarabine, and granulocyte-stimulating factor (AZA+HAG) in elderly patients with newly diagnosed acute myeloid leukemia ineligible for intensive chemotherapy: a multicenter, single-arm, phase 2 trial |
| Scientific title | Alternating treatment of venetoclax plus azacytidine (VA) with azacytidine plus homoharringtonine, low-dose cytarabine, and granulocyte-stimulating factor (AZA+HAG) in elderly patients with newly diagnosed acute myeloid leukemia ineligible for intensive chemotherapy: a multicenter, single-arm, phase… |
| Primary sponsor | Shenzhen second people‘s hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 2 |
| Countries | China |
| Conditions | acute myeloid leukemia |
| Interventions | treatment group:Alternate treatment with VA and AZA+HAG regimen |
| Registration date | Dec 25, 2024 |
| Target size | treatment group:96 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: